Pfizer Makes Big News With Small Step In Opioid Class
This article was originally published in RPM Report
Executive Summary
Congress is moving towards a comprehensive opioid abuse law, while the White House is taking administrative steps to expand treatment for addiction. Pfizer’s agreement on best practices for marketing opioids with the city of Chicago looks like a small step by comparison – but it has big implications.
You may also be interested in...
Drug Abuse And US Presidential Politics: Surprising Bipartisan Agreement
Donald Trump has a knack from making headlines, and produced a doozy when he called for drug tests of Hillary Clinton before the next Presidential debate; beneath the hoopla, however, was an important point of substance: the two campaigns actually agree that advancing addiction treatment is a high priority for federal action.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.